Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Liabilities from Discontinued Operations (2022 - 2024)

Historic Liabilities from Discontinued Operations for Bio Essence (BIOE) over the last 3 years, with Q1 2024 value amounting to $1.3 million.

  • Bio Essence's Liabilities from Discontinued Operations changed N/A to $1.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $976889.0 for FY2023, which is 1819.06% up from last year.
  • According to the latest figures from Q1 2024, Bio Essence's Liabilities from Discontinued Operations is $1.3 million.
  • In the past 5 years, Bio Essence's Liabilities from Discontinued Operations registered a high of $1.3 million during Q1 2024, and its lowest value of $826537.0 during Q4 2022.
  • For the 3-year period, Bio Essence's Liabilities from Discontinued Operations averaged around $1.0 million, with its median value being $976889.0 (2023).
  • Examining YoY changes over the last 5 years, Bio Essence's Liabilities from Discontinued Operations showed a top increase of 1819.06% in 2023 and a maximum decrease of 1819.06% in 2023.
  • Over the past 3 years, Bio Essence's Liabilities from Discontinued Operations (Quarter) stood at $826537.0 in 2022, then rose by 18.19% to $976889.0 in 2023, then surged by 37.75% to $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q1 2024, $976889.0 for Q4 2023, and $826537.0 during Q4 2022.